CPT® Code 86386

The CPT® Code 86386 refers to a qualitative screening test for Nuclear Matrix Protein 22 (NMP22). This test is specifically utilized in patients presenting with hematuria, which is the presence of blood in the urine. The primary purpose of the NMP22 test is to assist healthcare providers in distinguishing between hematuria caused by bladder cancer and hematuria resulting from other non-malignant conditions. NMP22 is a protein that resides within the cell nucleus, and its levels can be indicative of malignancy. In cases of bladder cancer, malignant neoplasms lead to an increase in intracellular NMP22 levels, which subsequently results in the shedding of this protein into the urine. To perform the test, a urine sample is collected from the patient, and a specialized test kit designed for NMP22 is employed to detect the presence or absence of the protein in the urine. Additionally, the test estimates the concentration of NMP22, with a level exceeding 7 being suggestive of a potential bladder malignancy. This screening test plays a crucial role in the early detection and diagnosis of bladder cancer, thereby facilitating timely intervention and management.